Loading
A phase 2 trial of ZEN-3694, Enzalutamide in prostate cancer, run by Zenith Epigenetics, now recruiting.
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT04986423 by Zenith Epigenetics, with 200 participants planned, started 2021-09-08 and due to reach its primary completion in 2026-12. Interventions recorded: ZEN003694, Enzalutamide. Conditions listed: Metastatic Castration-Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Zenith Epigenetics, ZEN-3694.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Metastatic castration-resistant prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.